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1 Introduction 
Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are common nasal inflammatory 
diseases. Despite differences in pathophysiology, clinical symptoms might resemble each 
other. Moreover, they are frequently associated (1). In recent years, different endotypes of 
these diseases, differentiated by distinct pathophysiological mechanisms, have been found. 
New therapeutic approaches aiming at the regulation of the inflammatory process on the 
level of cytokines and other mediators require endotyping of CRS and AR. Measuring 
cytokine levels in nasal secretions is a non-invasive and close-to-the-source method to learn 
more about the inflammatory processes in the individual patient’s nose. The present work 
contributes to the effort on finding biomarkers usable in individualised therapy.  
1.1  Disease characteristics 
The definition of AR is based on symptoms which include nasal obstruction and 
rhinorrhoea, nasal itching, and sneezing (2). These symptoms are reversible spontaneously 
or under treatment. The differential diagnoses of AR comprise CRS, infections, mechanical 
factors such as adenoidal hypertrophy, granulomas and tumours, ciliary defects, and 
cerebrospinal rhinorrhoea. AR is subdivided into intermittent and persistent disease with 
symptoms in intermittent disease being less frequent than four days a week or lasting for 
less than four consecutive weeks (3). Several risk factors such as familial history have been 
identified. However, AR remains a multifactorial burden. Ranking among the atopic 
syndromes, AR constitutes a risk for new onset asthma and more than one third of the AR 
patients in school age already suffer from concurrent atopic eczema or asthma (4). Besides, 
AR is often accompanied by asymptomatic bronchial involvement (5). 
CRS is an inflammation of the nose and the paranasal sinuses. In adults, CRS is clinically 
defined as having at least two symptoms for more than 12 weeks supported by endoscopic 
or radiological signs (1). These symptoms can be nasal congestion and discharge as well as 
facial pressure or pain and hyposmia. In primary care, the diagnosis is based on the patient’s 
symptoms. Nasal endoscopy or computed tomography scans demonstrating nasal polyps or 
mucosal changes may be added. However, these examinations are time-consuming and go 
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along with exposure to radiation, and thus are left to inexplicit cases. For research purposes, 
endoscopy is required to distinguish CRS with nasal polyps (CRSwNP) from CRS without 
nasal polyps (CRSsNP). CRS often occurs together with other diseases such as asthma, 
aspirin sensitivity, or immunocompromised state (1). Moreover, complications such as 
mucocoele formation or bone involvement may worsen the clinical picture.  
AR and CRS are well known to health centres in all parts of Europe as AR affects 23 % 
and CRS 11 % of the population (6, 7). Both significantly deteriorate patients’ quality of 
life, cause sick leaves, and impose notable direct and indirect cost to public health systems 
and society (8-10). Thus, research on effective therapeutic strategies might benefit 
individual patients as well as society. 
1.2  Cytokines 
In inflammation, cells and tissues use polypeptides named cytokines for intercellular 
communication. In 1957, Isaacs and Lindermann discovered interferon which was the first 
of dozens of cytokines that were found in the following decades (11). Cytokines are still 
subject to a wide variety of studies concerning their function, related and regulating genes, 
and possible therapeutic uses. Currently, this group of proteins contains interleukins (IL), 
chemokines, interferons (IFN), growth factors, tumour necrosis factors (TNF), and colony 
stimulating factors (CSF) (12). 
Cytokines are a heterogeneous group with some having pro-inflammatory, others anti-
inflammatory and modulating qualities. The properties of cytokines often are redundant 
and cause synergistic effects. Some cytokines have been found to be associated to certain 
cells of the innate or adaptive immune system. The following instances some of these. 
Antigen-presenting cells secrete amongst others TNF, IL-1, and IL-6 and thus activate 
granulocytes and lymphocytes, and induce acute-phase proteins (13). Fighting viruses and 
neoplastic cells, IFN- and IFN- are vital to the activity of natural killer cells and cluster 
of differentiation (CD) 8+ cytotoxic T cells. Besides, they induce pro-apoptotic genes (11). 
IFN-, on the other hand, is a signal molecule for T helper lymphocyte (TH) subclass 1. 
IFN- induces phagocytosis and thus contributes to cellular immunity (13). In anti-parasitic 
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and allergic immune response, eosinophilia, differentiation of naïve CD4+ cells into TH2, 
and up-regulated production of immunoglobulin (Ig)-E are seen. Amongst the cytokines 
made responsible for these processes are IL-4, IL-5, IL-13, and granulocyte-macrophage 
CSF (GM-CSF) (13). Moreover, chemokines are known to be an important factor. 
Eosinophil chemotactic protein (eotaxin) and others attract eosinophils to the site of 
inflammation (14). In contrast to the aforementioned cytokines, IL-10 has 
immunoregulatory properties. Primarily produced by regulatory T cells (Treg), IL-10 
suppresses secretion of pro-inflammatory cytokines and inhibits TH differentiation into TH1 
or TH2 (15). Keeping this knowledge on cytokine functions and their sources at the back of 
our minds, cytokine patterns can be drafted. These patterns are characterised by increased 
or reduced amounts of specific cytokines. Thus, the activity of particular cells of the 
immune system can be inferred from the measured amounts of cytokines. 
Cytokines mainly act in an autocrine or paracrine way at the site of inflammation. Thus, 
highest amounts are expected there. However, in high concentrations, some cytokines such 
as CSF execute endocrine functions.  
Several cytokine receptors have been discovered. Binding to its receptor in the cell 
membrane, a cytokine commences an intracellular biochemical cascade that activates 
transcription factors. Thus, expression of selected genes is initiated. Most receptors are 
specific for a certain cytokine. However, others have been found that are shared by different 
cytokines of the same family, which emphasises the redundant functions of several 
cytokines. 
Ensuring intercellular communication, cytokines contribute to maintaining homoeostasis. 
Moreover, they are crucial to the immune system when it comes to fighting infections. 
However, a disequilibrium of cytokines is potentially pathogenic and held responsible for 
a number of inflammatory diseases and autoimmune disorders, amongst them rheumatoid 
arthritis, allergy, multiple sclerosis, psoriasis, and sepsis (15, 16).  
While cytokines remain subject to current research, they are also of relevance concerning 
patient care. For multiple diagnostic and prognostic purposes, interleukins are quantified in 
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blood plasma and chemokines in cerebrospinal fluid (17). Experimentally, cytokines are 
measured in different body fluids and in tissue samples to learn more about 
pathophysiology or establish new diagnostic tools (18-20). While colony stimulating 
factors and interferons have been used as therapy for decades to treat diseases such as 
neutropenia or viral hepatitis, novel therapeutic approaches with monoclonal antibodies 
binding cytokines have been developed in recent years. Some are already established in 
patient care, such as anti-TNF antibodies in rheumatoid arthritis, others are on clinical trials 
(21). To select those patients who might be treated with specific antibodies, diagnostic tools 
measuring cytokine levels have to be established. 
1.3  Pathophysiology of AR 
The pathophysiology of AR is that of a type 1 immediate hypersensitivity reaction to 
aeroantigens.  
Prior to the allergic reaction, sensitisation is required. Antigen presenting cells process the 
antigen to peptides that are presented to naïve CD4+ T lymphocytes. These cells 
predominantly differentiate into TH2 lymphocytes which initiate B cell differentiation and 
induce Ig isotype switching. This results in the production of IgE.  
The early phase of allergic reaction is characterised by immediate cell activation. Within 
minutes, the allergen-IgE interaction activates prevailing IgE-coated mast cells, resulting 
in degranulation of a number of mediators. These mediators include tryptase, histamine, 
and neuropeptides, and are held responsible for boosted mucus production, vasodilatation, 
and increased vascular permeability. This causes the typical nasal symptoms that patients 
report such as rhinorrhoea or nasal congestion.  
In the course of the allergic reaction, released cytokines recruit inflammatory cells such as 
T lymphocytes, granulocytes, and monocytes. Attracted by chemokines such as eotaxin, 
regulated on activation, normal T cell expressed and secreted (RANTES), and macrophage 
inflammatory protein (MIP)-1, eosinophils migrate into the nasal mucosa. Activated 
eosinophils release granules containing mediators e.g. eosinophil cationic protein (ECP) 
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that can cause damage to nasal epithelial cells (22). In addition, they produce cytokines 
inducing migration and activation of inflammatory cells. Thus, a pro-allergic milieu is 
maintained. In contrast to the early phase, this late reaction generates a persistent 
inflammation resulting in nasal hyperresponsiveness.  
In AR, a disequilibrium of different T cell subsets is held responsible for the pathological 
reactions. The lymphocyte population is dominated by TH2, and increased levels of the TH2 
associated cytokines IL-4, IL-5, IL-13, and eotaxin have been measured (23). In contrast, 
normal or even reduced levels of TH1 associated cytokines have been found, indicating an 
imbalance of these two types of T helper cells (23). A recently found subtype of T helper 
cells, named TH17, produces the pro-inflammatory cytokine IL-17. With regard to this 
subtype, findings are inconsistent and their role in allergy remains to be elucidated (23, 24). 
Tregs, another lymphocyte subtype, suppresses both TH1 and TH2-type cytokine expression 
via inhibitory cytokines and has even the ability to inhibit inflammatory cells by direct cell 
interaction. Concerning Tregs, a disequilibrium in comparison to the amount of TH2 cells 
has been suspected (22). 
1.4  Pathophysiology of CRS 
Based on endoscopy, CRS is divided into CRSsNP and CRSwNP. Research on pathology 
and histology of CRS revealed both to be different disease entities and thus confirmed this 
subdivision.  
The aetiology of CRS is not yet entirely understood. Different hypotheses contemplate T 
cell activation in response to microbial antigens or environmental factors, and a 
dysregulation of the immune barrier (1). In fact, patients suffering from CRSwNP were 
found to have increased colonisation with Staphylococcus aureus (25). However, the 
impact of microorganisms in CRS remains to be proven. Currently, CRS is described as a 
multifactorial disease in which misguided interactions between host, pathogens, and 
exogenous stress contribute (1). 
In CRSsNP, a TH1-dominated milieu is found, and levels of the TH1-associated cytokine 
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IFN- are reported to be elevated. The Treg population is – in contrast to CRSwNP – 
reported to be normal (25). Fibrosis is dominating the histological picture. In addition, 
basement membrane thickening, subepithelial oedema, and infiltration of inflammatory 
cells such as monocytes and neutrophils is seen.  
On the other hand, CRSwNP presents an eosinophilic inflammation with high amounts of 
TH2-associated cytokines amongst these IL-4, IL-5, and IL-13. Mainly produced by 
lymphocytes, IL-5 is held responsible for the local survival of eosinophils (26). Moreover, 
a diminished population of Tregs is found in polyps, possibly due to attenuated migration 
(25). A dysregulation of epithelial immune barrier function and chemokine production is 
also suspected (1). However, the aforesaid only refers to the Caucasian population. Studies 
on Asians show a TH2 negative but TH1/ TH17 predominated neutrophilic inflammation in 
the majority of cases (25, 27). Thus, subdivision within the CRSwNP subgroup appears 
necessary. Macroscopically, in the nasal cavity, the polyps can be easily identified as 
greyish protuberances. Preparation of tissue samples reveals oedema in stromal tissue as 
well as pseudocysts, epithelial damage, and inflammatory cell infiltration.  
With new therapies emerging, research on the pathophysiology and endotyping of CRS 
appears more vital than ever. 
1.5  Methodological approach 
Produced by goblet cells and seromucous glands, nasal secretions moisten and clear the air. 
In disease, an increased amount of secretions is produced and leaked plasma contents may 
contribute to the secretions. Different methods are used to investigate pathologies of the 
nose. For research purposes, cells and tissues as well as nasal secretions are examined. 
Immunocyto- or -histochemistry and PCR can be performed on cells gained by scraping 
with cotton swab or cytobrush, and in tissue samples. However, cytology and histology 
proved to be in an inferior position compared to mediators and cytokines in nasal secretions 
when differentiation between nasal diseases is required (28). Methods to obtain secretions 
are non-invasive and include nasal lavage with physiological saline and the use of 
absorptive materials. In contrast to simple nasal blowing and vacuum suction, the 
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aforementioned methods extract a sufficient amount of secretion (29). The cotton wool 
pieces used in the present studies gain secretions by capillary suction. This method was 
chosen because it is non-invasive and least uncomfortable for the patient.  
The exposure to aeroallergens is not only dependent on the absolute concentration in the 
air but also to the patient’s habits and attempts to abstention. Thus, determining the exact 
pollution with antigens the patient is exposed to is not feasible. Earlier studies employed 
allergen or histamine challenge before taking samples (23, 30, 31). This results in 
increasing cytokine release. However, the pace of increase differs in between the 
biomarkers and for some, peak concentrations are not reached until several hours after 
provocation (23). This requires taking multiple samples and constitutes a time-consuming 
approach. Thus, this does not well meet the demands that would be made in an actual 
clinical use. To obtain a true-to-life setting, AR subjects were thus examined irrespective 
of the season and without prior allergen or histamine challenge.  
This methodological approach unites a technique that is easy to perform, cheap, and small 
in discomfort for the patient, with a true-to-life setting without demands concerning the 
time of sampling. These features make it well applicable in clinical routine.  
1.6  Current therapy options 
Concerning AR, the physician is provided with a bunch of treatment options. Apart from 
avoiding allergen exposure, current guidelines recommend oral H1-antihistamines, 
intranasal application of glucocorticoids, and leukotriene-receptor antagonists (2). 
However, one to two thirds of patients experience only partial relief by medication (32). 
Moreover, for severe AR, immunotherapy is available. New approaches in research of AR 
therapy focus on biopharmaceuticals such as monoclonal antibodies. Patients suffering 
from seasonal AR (SAR) are shown to benefit from treatment with omalizumab, a 
humanised anti-IgE antibody (2). Moreover, studies targeting IL-4, IL-5, and IL-13 are 
conducted (32). 
Current therapy options in CRS aim to achieve and maintain control of the disease. The 
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therapeutic standard is topical glucocorticoids (1). Besides, saline sprays may be used to 
appease discomfort. Despite the aforementioned hypothesis of microbial involvement in 
the aetiology of CRS, studies on antibiotic treatment did not show sweeping success (1). 
Due to unclear effectivity, no recommendation for antibiotics in the therapy of CRS exists. 
Regrettably, conservative treatment still shows poor success rates, with more than half of 
the patients not responding adequately to medication (33). After abortive medical 
treatment, sinus surgery preserving normal mucosa is recommended to restore sinus 
ventilation and drainage (21). In recent years, research on biopharmaceuticals made 
headway. Studies on humanised monoclonal antibodies directed against IgE, IL-5, and the 
IL-4 receptor  showed auspicious results in small study populations (21). Currently, proof 
of concept studies as well as clinical trials are conducted regarding effectivity and safety of 
these biopharmaceuticals. However, further research is needed to evaluate the relevance of 
the particular biopharmaceuticals and to establish biomarkers that predict the response to 
this treatment.  
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2 Abstract 
2.1  Background 
Both AR and CRS rank among the most common nasal diseases. In AR, the inflammatory 
reaction presents itself with tissue eosinophilia and a disequilibrium of T lymphocytes with 
TH2 cells predominating. CRSsNP is characterised by a TH1 milieu. In contrast, CRSwNP 
shows a TH2 driven eosinophilic inflammation. With new therapeutic approaches using 
biopharmaceutics emerging, determination of biomarkers is required to select patients 
suitable for these therapies. 
2.2  Objective  
Aim of the present studies was to describe disease-specific cytokine patterns in nasal 
secretions. Therefore, levels of mediators and cytokines regulating T lymphocytes or 
stimulating inflammatory cells were measured in different nasal diseases including SAR, 
perennial AR (PAR), CRSsNP, and CRSwNP, and in healthy controls. 
2.3  Methods 
Study population: 230 volunteers participated in both studies, whereof 44 suffered from 
SAR, 45 from PAR, 48 from CRSsNP, 45 from CRSwNP, and 48 were healthy controls. 
AR was ascertained by patient history and a positive skin prick test and, according to the 
allergens tested positive, rated into the SAR or PAR group. CRS was determined by patient 
history, inspection of the nose and nasal endoscopy revealing the presence or absence of 
polyps. Thus, subdivision into CRSsNP and CRSwNP was made. Healthy controls 
presented no history of nasal complaints, normal findings in the endoscopic examination, 
and a negative in vitro allergy screening test. Medication addressing the nasal disease six 
weeks prior to the examination, purulent rhinitis, and the presence of a mixed AR-CRS 
disease pattern constituted exclusion criteria. 
Biochemical and immunological methods: Nasal secretions were gained by using cotton 
wool pieces placed in the middle meatus of the nose for 20 min. Samples were extracted 
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using centrifugation, and all samples were diluted 1:5 due to the partially small volumes. 
To determine the amounts of cytokines, a human cytokine 27-plex panel was utilised. This 
panel uses fluorescently-addressed polystyrene beads with conjugated capture antibodies 
directed to specific cytokines. The samples were analysed for IL-1, IL-4, IL-5, IL-6, IL-
8, IL-10, IL-12, IL-13, IL-17, GM-CSF, granulocyte CSF (G-CSF), IFN-, monocyte 
chemotactic protein (MCP)-1, MIP-1, MIP-1, eotaxin, and RANTES. The amounts of 
ECP and tryptase were quantified by ELISA. 
Statistics: For statistical evaluation and graphical presentation, Sigma Plot version 11.0 
software was utilised. 
2.4  Results 
In AR, nasal secretions were examined with regard to T lymphocyte-related cytokine 
patterns. Concerning the amount of the TH1-associated biomarkers IL-12 and IFN-, a 
decrease could be demonstrated in nasal secretions of participants suffering from SAR 
compared to both PAR and controls. With regard to TH2-associated cytokines, SAR 
presented elevated levels of IL-5 and decreased amounts of IL-13. The quantity of IL-4 was 
lowered in PAR. Concerning the other T cell associated cytokine patterns, decreased levels 
of the Treg related cytokine IL-10, and elevated amounts of the TH17 indicating cytokine 
IL-17 were found in SAR while PAR and the controls did not differ. Several degranulation 
products and cytokines indicating inflammatory cell activation were investigated. In AR, 
irrespective of seasonal or perennial disease, the levels of MCP-1, MIP-1, ECP, and 
tryptase were elevated over the controls. SAR only presented increased amounts of MIP-
1. In SAR, RANTES and eotaxin were elevated over PAR, while no significant difference 
between either of the AR groups and controls was calculated. The levels of IL-1, IL-6, 
GM-CSF, and G-CSF did not differ between the three groups.  
In CRS, the TH2 associated cytokines also showed a heterogeneous picture. IL-4 showed 
no significant differences between the groups, IL-5 was increased in CRSwNP over 
CRSsNP, and IL-13 was reduced in both CRS groups. Nasal secretions from participants 
suffering from CRSwNP showed lower quantities of the TH1 and Treg associated cytokines 
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IL-12 and IFN-, and IL-10, respectively, compared to both CRSsNP and controls. 
However, IL-17, indicating TH17 activity, was elevated in CRSwNP. As markers of 
inflammatory cell activation, levels of MCP-1, MIP-1, G-CSF, ECP, and tryptase were 
elevated in CRSwNP, and the quantity of MIP-1 was increased in both CRS groups. 
RANTES was found to be increased in CRSsNP over controls. The measurement of IL-8, 
eotaxin, and GM-CSF did not show any differences among groups. 
2.5  Conclusions 
In both AR and CRS, the disease can be pictured by cytokines in nasal secretions. Pro-
inflammatory cytokines were evidently elevated in AR. ECP and tryptase, as well as MCP-
1 and MIP-1 clearly distinguished between healthy subjects and those suffering from AR. 
The levels of RANTES allowed to differentiate between SAR and PAR. Yet, a more 
pronounced inflammatory profile could be demonstrated in SAR, indicating a higher degree 
of inflammatory reaction in this disease entity. Moreover, the data on hand suggests a 
disequilibrium of T cells in SAR where a downregulation of TH1 and Treg as well as an 
upregulation of TH17 is displayed by their respective cytokines. Furthermore, intensified 
eosinophil and mast cell activity is displayed.  
Similarly, inflammation in CRS presents itself in nasal secretions. Altogether, CRSwNP 
showed a more distinct cytokine profile than CRSsNP, the latter differed only in two 
biomarkers from the healthy controls, RANTES and MIP-1. This study on CRSwNP 
showed elevated levels of IL-5 and IL-17 combined with low levels of IL-10, IL-12, and 
IFN- in CRSwNP. Thus, it adumbrates an imbalance of T helper cells accompanied by a 
downregulation of Tregs. Moreover, the elevation of various cytokines illustrated the 
activity of different inflammatory cells in CRSwNP.  
The present work shows that not only the inflammation, but also the T cell disequilibrium 
can be detected in cytokine profiles in nasal secretions. Moreover, it demonstrates that 
cytokines differentiate between inflammatory nasal diseases. Thus, examination of 
cytokine profiles in nasal secretions may constitute a helpful tool in diagnosis and prognosis 
of sinonasal diseases. Moreover, it constitutes a technique applicable to further research on 
the pathology of those diseases.                                   
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3 Zusammenfassung 
3.1  Hintergrund 
Sowohl die allergische Rhinitis als auch die chronische Rhinosinusitis gehören zu den 
häufigsten Erkrankungen der Nase. Die Entzündungsreaktion bei der allergischen Rhinitis 
ist durch Eosinophilie und ein Ungleichgewicht der T-Lymphozyten gekennzeichnet, 
wobei hier TH2-Zellen vorherrschen. Bei der CRSsNP sind TH1-Lymphozyten der 
dominierende Zelltyp. Die CRSwNP zeigt hingegen eine Entzündungsreaktion, welche von 
TH2-Zellen und Eosinophilen geprägt ist. Gegenstand derzeitiger Forschung zur 
Behandlung dieser Erkrankungen sind neue Biopharmazeutika wie monoklonale 
Antikörper. Hieraus ergibt sich die Notwendigkeit der Forschung an Biomarkern, denn mit 
geeigneten Biomarkern können jene Patienten herausgefiltert werden, die sich für eine 
solche Therapie eignen. 
3.2  Zielsetzung 
Ziel der vorliegenden Studien war es daher, krankheitsspezifische Zytokinprofile im 
Nasensekret zu beschreiben. Hierfür wurden Zytokine und Botenstoffe bestimmt, welche 
die T-Zell-Aktivität regulieren oder Entzündungszellen stimulieren. Neben gesunden 
Kontrollen umfassten die Studien Patienten mit SAR, PAR, CRSsNP und CRSwNP. 
3.3  Methoden 
Studienteilnehmer: An den Studien nahmen 230 Freiwillige teil, die sich in folgende 
Gruppen einteilen ließen: 44 Teilnehmer litten unter SAR, 45 unter PAR, 48 unter CRSsNP 
und 45 unter CRSwNP. Die Kontrollgruppe umfasste 48 Personen. Die Diagnose AR 
wurde nach der Erhebung der Anamnese gestellt und setzte einen positiven Prick-Test 
voraus. In Abhängigkeit von den positiv getesteten Allergenen wurden die Teilnehmer der 
SAR- oder PAR-Gruppe zugeteilt. Zur Ermittlung des Vorliegens einer CRS wurden neben 
der Anamnese eine Inspektion sowie eine Endoskopie der Nase vorgenommen. Hierdurch 
konnte das Vorliegen von Polypen festgestellt oder ausgeschlossen und die Patienten der 
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jeweiligen Gruppe zugeordnet werden. Die Teilnehmer in der Kontrollgruppe verneinten 
nasale Beschwerden in der Krankengeschichte und zeigten Normalbefunde in der 
Endoskopie der Nase. Ein In-vitro-Screening auf Allergien fiel zudem negativ aus. 
Teilnehmer mit einer purulenten Rhinitis wurden ebenso von der Studie ausgeschlossen 
wie Teilnehmer, die in den letzten sechs Wochen vor der Untersuchung Medikamente 
verwendet hatten, welche eine Erkrankung der Nase oder der Nasennebenhöhlen 
beeinflussen konnten. Ebenfalls ausgeschlossen wurden Teilnehmer, welche ein 
gemischtes Krankheitsbild mit AR und CRS aufwiesen. 
Biochemische und immunologische Methoden: Das Nasensekret wurde mittels 
medizinischer Watte aus Baumwollgewebe, die für 20 min in den mittleren Nasengang 
eingeführt und anschließend zentrifugiert wurden, gewonnen. Da hierbei teilweise nur 
geringe Volumina erzielt wurden, wurden die Proben 1:5 verdünnt. Mittels eines Human 
Cytokine 27-Plex Panel wurden die im Nasensekret enthaltenen Zytokine quantifiziert. Bei 
diesem Verfahren kommen an fluoreszierende Polystyrenkügelchen gebundene Antikörper 
zum Einsatz, welche sich gegen die jeweiligen Zytokine richten. Für die vorliegenden 
Studien wurden folgende Zytokine untersucht: IL-1, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, 
IL-13, IL-17, GM-CSF, G-CSF, IFN-, MCP-1, MIP-1, MIP-1, Eotaxin und RANTES. 
Des Weiteren wurden ELISAs zur Messung von ECP und Tryptase verwendet.  
Statistik: Zur statistischen Auswertung und zum Erstellen der Grafiken wurde das 
Programm Sigma Plot Version 11.0 verwendet.  
3.4  Ergebnisse 
Die Nasensekrete der AR-Patienten wurden in Hinblick auf Zytokinprofile von T-
Lymphozyten untersucht. Hinsichtlich der TH1-zugeordneten Zytokine IL-12 und IFN- 
konnte in der SAR ein gegenüber der PAR und der Kontrollgruppe signifikant erniedrigtes 
Niveau gezeigt werden. Bei den TH2-zugeordneten Zytokinen ergaben die Messungen in 
der SAR-Gruppe erhöhte Werte für IL-5 und erniedrigte für IL-13. IL-4 war in der PAR-
Gruppe erniedrigt. Was die anderen T-Zellen anbelangte, zeigte sich eine Erniedrigung des 
Treg-zugeordneten Zytokins IL-10 in der SAR, während das TH17-spezifische Molekül IL-
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17 erhöht war. Zwischen PAR und der Kontrollgruppe fanden sich für diese Biomarker 
keine Unterschiede. Neben Zytokinen, die auf eine T-Zell-Aktivität schließen lassen, 
wurden auch Zytokine und Botenstoffe untersucht, die ein Wirken anderer 
Entzündungszellen nahe legen. Unabhängig davon, ob eine Sensibilisierung gegen ein 
saisonal oder ganzjährig auftretendes Allergen vorlag, zeigten sich im Vergleich zur 
Kontrollgruppe erhöhte Werte für MCP-1, MIP-1, ECP und Tryptase. Einzig die SAR-
Patienten wiesen eine Erhöhung von MIP-1 auf. Zudem waren RANTES und Eotaxin in 
der SAR höher als bei PAR, es bestand jedoch kein signifikanter Unterschied zur 
Kontrollgruppe. Für IL-1, IL-6, GM-CSF und G-CSF ergaben sich keine Unterschiede 
zwischen den Gruppen. 
Bei der Untersuchung der CRS wurden ebenfalls die TH2-zugeordneten Zytokine 
gemessen. Hier zeigten sich für IL-4 keine Unterschiede zwischen den Gruppen, während 
sich IL-5 in der CRSwNP im Vergleich zur CRSsNP erhöht zeigte. IL-13 war im 
Nasensekret beider CRS-Gruppen erniedrigt. Im Vergleich zur Kontrollgruppe und zu 
CRSsNP zeigten die TH1- und Treg-zugeordneten Zytokine IL-12, IFN- und IL-10 
signifikant niedrigere Werte in der Gruppe CRSwNP. IL-17, das eine Aktivität der TH17-
Zellen anzeigt, war in dieser Gruppe hingegen erhöht. Von den Botenstoffen, die eine 
Aktivierung verschiedener Entzündungszellen anzeigen, waren MCP-1, MIP-1, G-CSF, 
ECP und Tryptase bei Patienten, die unter CRSwNP litten, erhöht. In beiden CRS-Gruppen 
wurden höhere Werte für MIP-1 gemessen als in der Kontrollgruppe. In der CRSsNP war 
RANTES im Vergleich zur Kontrollgruppe erhöht. Für IL-8, Eotaxin und GM-CSF zeigten 
sich keine Unterschiede zwischen den Gruppen. 
3.5  Fazit 
Die vorliegenden Studien konnten zeigen, dass sich die Erkrankungen sowohl im 
Nasensekret von AR-Patienten als auch in dem von CRS-Patienten darstellen lassen. In 
beiden AR-Gruppen waren die entzündungsfördernden Zytokine deutlich erhöht. Mittels 
ECP, Tryptase, MCP-1 sowie MIP-1 konnte eindeutig zwischen der Kontrollgruppe und 
den AR-Gruppen unterschieden werden. Zudem erlaubten die für RANTES gemessenen 
Werte eine Unterscheidung von SAR und PAR. Im Nasensekret der SAR-Patienten zeigte 
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sich die Entzündungsreaktion stärker als in dem der PAR-Probanden. Dies lässt darauf 
schließen, dass die Entzündungsreaktion in dieser Gruppe deutlich stärker ist. Zudem 
bilden die vorliegenden Ergebnisse ein gestörtes Gleichgewicht der T-Zellen ab. TH1- und 
Treg-Lymphozyten scheinen vermindert aktiv zu sein, während die Erhöhung von IL-17 auf 
eine gesteigerte Aktivierung der TH17-Zellen hinweist. Daneben zeigt sich eine verstärkte 
Aktivität von Mastzellen und Eosinophilen.  
Auch bei CRS zeigte sich die Entzündung im Nasensekret. Mit Blick auf die Ergebnisse 
lässt sich sagen, dass die Entzündungsreaktion bei den Patienten mit CRSwNP deutlicher 
hervortrat als bei jenen Patienten ohne Polyposis, bei denen sich ein signifikanter 
Unterschied zur Kontrollgruppe nur für zwei Zytokine, RANTES und MIP-1, zeigte. Im 
Nasensekret der CRSwNP-Patienten ließen sich erhöhte Werte für IL-5 und IL-17 
nachweisen. Gemeinsam mit den erniedrigten Werten für IL-10, IL-12, und IFN- weist 
dieses Zytokinprofil auf ein unausgeglichenes Verhältnis der T-Helferzellen und eine 
verminderte Aktivität der Tregs bei CRSwNP hin. Auch legt die Erhöhung unterschiedlicher 
Botenstoffe nahe, dass verschiedene Immunzellen die Entzündung unterhalten.  
Zusammenfassend kann gesagt werden, dass sowohl die Entzündung selbst als auch ein 
gestörtes Gleichgewicht der T-Lymphozyten anhand des Zytokinprofils im Nasensekret 
dargestellt werden können. Zudem kann mittels Zytokinprofilen zwischen verschiedenen 
Erkrankungen der Nase unterschieden werden. Daher könnte sich die Untersuchung von 
Zytokinen in Bezug auf AR und CRS als diagnostisch und prognostisch wichtiges 
Werkzeug erweisen. Zudem ist die hier verwendete Methode ein geeignetes Mittel für 
weitere Forschung über die Pathologie nasaler Krankheiten. 
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4 Prospects 
Currently, new therapies targeting cytokines are emerging. This generates need for reliable 
and uncomplicated methods to identify patients who might benefit from these therapies. 
One of these methods suitable for clinical practice is the cotton-wool method to gain nasal 
secretions as it is easy to handle, non-invasive, and cheap. Moreover, analysing cytokines 
by multiplex assays provides data rapidly and reproducibly. The conducted studies provide 
evidence that inflammation is depicted in nasal secretions. Hence, the utilised methods 
constitute techniques which also meet the needs of researchers. On the one hand, further 
research is required for clinical purposes as biomarkers are needed for differential 
diagnosis, prognosis, and matching anti-cytokine therapies to the individual patient. On the 
other hand, research on cytokines in nasal secretions provides the opportunity to learn more 
about the pathophysiology of nasal diseases. Understanding the underlying mechanisms, 
new therapies can be developed, and possibly even prevention can be initiated. Two key 
approaches should be adopted. Firstly, healthy individuals have to be examined to establish 
norm values. According to the findings of the present studies, these norm values need to 
include data on the interleukins 5, 10, 12, and 17, on IFN-, RANTES, MCP-1, MIP-1, 
MIP-1, ECP, and tryptase. Yet, this is easily done in an automated fashion using cytokine 
assays, once the samples are collected using the highly convenient cotton-wool method. In 
addition, cytokine profiles should be measured in other nasal diseases such as acute rhinitis, 
cystic fibrosis, or neoplastic diseases. The next step would be to study cytokine profiles in 
individuals suffering from overlapping disease. Thereby, conclusions could be drawn about 
the impact of each disease in the individual patient. Thus, therapies tailored to the 
individual patient’s needs could be initiated.  
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Abstract 
Background: New therapeutic approaches with biologic agents such as anti-cytokine antibodies are currently on 
trial for the treatment of asthma, rhinosinusitis or allergic diseases necessitating patient selection by biomarkers. 
Allergic rhinitis (AR), affecting about 20 % of the Canadian population, is an inflammatory disease characterised by a 
disequilibrium of T-lymphocytes and tissue eosinophilia. Aim of the present study was to describe distinct cytokine 
patterns in nasal secretion between seasonal and perennial AR (SAR/PAR), and healthy controls by comparing 
cytokines regulating T-cells or stimulating inflammatory cells, and chemokines.
Methods: Nasal secretions of 44 participants suffering from SAR, 45 participants with PAR and 48 healthy controls 
were gained using the cotton wool method, and analysed for IL-1β, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, GM-CSF, 
G-CSF, IFN-γ, MCP-1, MIP-1α, MIP-1β, eotaxin, and RANTES by Bio-Plex Cytokine Assay as well as for ECP and tryptase 
by UniCAP-FEIA.
Results: Participants with SAR or PAR presented elevated levels of tryptase, ECP, MCP-1, and MIP-1β, while values of 
GM-CSF, G-CSF, IL-1β, and IL-6 did not differ from the controls. Increased levels of IL-5, eotaxin, MIP-1α, and IL-17 and 
decreased levels of IFN-γ, IL-12 and IL-10 were found in SAR only. RANTES was elevated in SAR in comparison to PAR. 
Interestingly, we found reduced levels of IL-4 in PAR and of IL-13 in SAR.
Conclusions: Elevated levels of proinflammatory cytokines were seen in both disease entities. They were, however, 
more pronounced in SAR, indicating a higher degree of inflammation. This study suggests a downregulation of TH1 
and Treg-lymphocytes and an upregulation of TH17 in SAR. Moreover, the results display a prominent role of eosino-
phils and mast cells in AR. The observed distinct cytokine profiles in nasal secretion may prove useful as a diagnostic 
tool helping to match patients to antibody therapies.
Keywords: Allergic rhinitis, Nasal secretion, Mediators, Cytokines, Chemokines, Interleukins
© 2015 König et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Allergic rhinitis (AR) is a common disorder of the nose. 
Patients’ symptoms include nasal obstruction, rhinor-
rhoea, sneezing and nasal itching. All of them are revers-
ible spontaneously or under treatment. AR is subdivided 
into intermittent and persistent disease. Intermittent 
disease is defined by the patient having symptoms for 
less than 4 days a week or for less than 4 weeks [1]. It is 
estimated that 400 million people worldwide are affected, 
with a prevalence of AR of about 20  % in Canada and 
23  % in Europe [2–4]. Todo-Bom et  al. [5] found that 
intermittent and persistent disease are equally frequent 
in adults. AR is often associated with asthma, sinusitis, 
otitis media or nasal polyps and has a significant impact 
on patients’ quality of life [1, 6]. In addition, the disease 
imposes a substantial economic burden for society [7].
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#e underlying pathology of AR is known to be a 
type 1 immediate hypersensitivity reaction. During 
the period of sensitisation, the allergen is presented 
to CD4+ T-lymphocytes inducing differentiation to 
the T-helper cell (TH) 2 phenotype. TH2-lymphocytes 
secrete cytokines which promote the differentiation 
of B cells as well as induce immunoglobulin (Ig) syn-
thesis and regulate Ig isotype switching. #is results 
in increased levels of specific IgE, both local and sys-
temic [8]. In the early-phase of allergic reaction, mast 
cells, coated with specific IgE, recognise the allergen 
and release several mediators such as histamine and 
tryptase. In contrast, the late-phase is characterised by 
the secretion of chemokines like eosinophil chemotac-
tic protein (eotaxin), “regulated on activation, normal 
T cell expressed and secreted” (RANTES), and mac-
rophage inflammatory protein-1α (MIP-1α) [9], which 
induce the recruitment of eosinophils and other inflam-
matory cells. Activated eosinophils release granules 
containing amongst others eosinophil cationic protein 
(ECP) and major basic protein (MBP) [10]. In addi-
tion, eosinophils synthesise and secrete cytokines, e.g. 
interleukin (IL)-5 or granulocyte–macrophage colony-
stimulating factor (GM-CSF). Whereas the early-phase 
response to allergen exposure leads to acute symptoms, 
the late-phase reaction is held responsible for persisting 
inflammation.
AR is determined by a disequilibrium of T-helper cells 
with a predominance of TH2-type cytokines but normal 
levels of TH1-type cytokines. Another subtype of T-cells, 
regulatory T-cells (Treg), suppresses both TH1 and TH2-
type cytokine expression [11]. #us, it has been suggested 
that in AR, an imbalance between TH2 and Treg-cells 
exists as well [10]. Concerning TH17-lymphocytes, some 
authors found elevated levels of IL-17. However, the find-
ings on IL-17 are ambiguous and the role of TH17-cells in 
AR remains unclear [12, 13].
Aim of the present study was to investigate whether 
in AR caused by a seasonal (SAR) or a perennial (PAR) 
allergen, representative cytokines and mediators in 
nasal discharge show distinct patterns picturing the 
pathophysiology. #erefore, we analysed the levels of 
cytokines and other inflammatory mediators in the nasal 
fluid of participants suffering from SAR or PAR, focus-
ing on three main topics: cytokines (1) regulating TH1 
(interferon-γ (IFN-γ), IL-12), TH2 (IL-4, IL-13), Treg (IL-
10), and TH17 (IL-17) cells, or (2) stimulating and acti-
vating inflammatory cells like granulocytes and mast 
cells (granulocyte colony-stimulating factor (G-CSF), 
GM-CSF, IL-1β, IL-5, and IL-6), and (3) chemokines 
such as eotaxin, RANTES, monocyte chemotactic pro-
tein-1 (MCP-1), or MIP-1α/β.
Methods
Study population
Clinical history was taken by one of the investigators. 
Patients presenting a history of chronic rhinosinusitis, 
nasal polyposis or aspirin sensitivity were excluded from 
the study (Table 1). Any medication concerning the nasal 
disease during 6 weeks prior to the examination consti-
tuted an exclusion criterion, especially anti-inflamma-
tory medication such as nasal steroids or antihistamines. 
Also, nasal endoscopy was performed in all participants 
in order to assess clinical signs of rhinitis and to exclude 
patients with signs of purulent rhinitis or polyposis. After 
exclusion, 137 volunteers (73 males, 64 females, mean 
age 38 ± 16 years) participated in this study.
AR was determined by the participant’s history and 
by a positive skin prick test (SPT) (ALK-Abelló, Wedel, 
Germany) for the following allergens: timothy grass, rye, 
birch, hazel, alder, beech, mugwort, ribwort, nettle, dan-
delion, house dust mite, storage mite, dog, cat and horse 
epithelial dander, alternaria, aspergillus, cladosporium, 
and penicillium; histamine dihydrochloride solution at 
1 mg/ml as positive control and allergen-free saline solu-
tion as negative control were used. #e SPT was consti-
tuted positive if the diameter of the wheal was >3  mm. 
#ereafter, specific IgE to allergens tested positive in 
skin prick test was measured in serum (UniCAP-FEIA, 
Phadia, Freiburg, Germany).
SAR (n  =  44) was determined by sensitisation to at 
least one seasonal allergen with a positive skin prick 
test and a compatible positive specific IgE measure-
ment (≥0.8 kU/l) as well as typical seasonal complaints 
in participant’s history. If patient’s history did not allow a 
definite rating of the seen sensitisation with respect to its 
clinical relevance, a intranasal challenge to the suspected 
allergen was performed. Participants additionally sensi-
tised to a perennial allergen were excluded.
PAR (n  =  45) was determined by participant’s his-
tory, a sensitisation to house dust mite, animal dander, 
or perennial mold like aspergillus with a positive skin 
prick test and a specific IgE  ≥  0.8 kU/l. Moreover, an 
intranasal allergen challenge was performed in case of a 
sensitisation to house dust mite or perennial mold, or a 
Table 1 Exclusion criteria
All groups Chronic rhinosinusitis
Nasal polyposis
Aspirin sensitivity
Purulent rhinitis
Specific medication during the last 6 weeks
SAR Sensitisation to perineal allergen
PAR Sensitisation to seasonal allergen
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sensitisation to animal dander whose clinical relevance 
could not be clearly rated by patient’s history. Partici-
pants additionally sensitised to a seasonal allergen were 
excluded.
Healthy controls (n  =  48) presented no history of 
inflammatory nasal complaints and a negative in  vitro 
allergy screening test Sx1 (Phadia, Freiburg, Germany).
Samples were collected during as well as outside pol-
len season. Collection was not done in relation to actual 
allergen exposure or actual complaints.
#e study was approved by the ethics committee of 
the medical faculty of Ludwig-Maximilians-University 
and written informed consent was obtained from all 
participants.
Biochemical and immunological methods
For sampling of nasal fluids, the cotton wool method was 
performed with minor modifications as invented by Rasp 
and coworkers [14]. Nasal secretions were gained as pre-
viously described using small cone-shaped cotton wool 
pieces (absorbent cotton, Hartmann, Heidenheim/Brenz, 
Germany) with a length of about 3  cm and a diameter 
of about 6 mm [15]. Introduced into the middle meatus 
of the nose, the cotton wool pieces were left in place for 
20 min and were subsequently centrifuged (+4 °C, 2000g) 
on a sieve for 10 min [16].
Because of partially small volumes, all samples were 
diluted 1:5 and were analysed for IL-1β, IL-4, IL-5, IL-6, 
IL-10, IL-12, IL-13, IL-17, GM-CSF, G-CSF, IFN-γ, 
MCP-1, MIP-1α, MIP-1β, eotaxin, and RANTES using 
a human cytokine 17-plex panel (Bio-Plex Cytokine 
Assay, Bio-Rad Laboratories, Hercules, California). #e 
cytokine assay uses fluorescently-addressed polystyrene 
beads with conjugated capture antibodies directed to the 
above-mentioned cytokines. After washing, a fluores-
cently marked detection antibody builds an immunoas-
say with the cytokine. For analysis, two lasers excite the 
fluorochromes: one for classifying each bead, the other 
for quantifying the amount of analyte bound [17]. Detec-
tion levels were 0.5 pg/ml.
ECP and tryptase were measured by ELISA (UniCAP-
FEIA, Phadia, Freiburg, Germany). #resholds for detec-
tion were 10 ng/ml for ECP and 5 ng/ml for tryptase.
Statistics
SigmaPlot for Windows version 11.0 software (Systat 
Software, San José, California, USA) was used for sta-
tistical evaluation and graphical presentation. All data 
failed normality testing (Shapiro–Wilk). #erefore, the 
Kruskal–Wallis One Way Analysis of Variance (ANOVA) 
on Ranks was used for testing a statistically significant 
difference in the median values among the three groups. 
To isolate the group or groups that differ from the 
others, the All Pairwise Multiple Comparison Procedures 
(Dunn’s Method) was used in the following step. p values 
<0.05 were regarded as significant. For graphic presenta-
tion of results, data is given in a box plot with the median 
(horizontal line within the box), the 25th and 75th per-
centile (boundary of the box), and the 10th and 90th per-
centile (whiskers above and below the box). Significances 
are graphically represented between the corresponding 
plots: * indicates p value <0.05, ** p value <0.01, and *** p 
value <0.001.
Results
44 participants suffering from SAR, 45 participants suf-
fering from PAR and 48 healthy subjects were included 
in this study. Demographics and sensitisation profiles 
are depicted in Table  2. #e mean age varied from 36 
to 40  years. #e highest percentage of subjects suffer-
ing from asthma was found in the SAR group, followed 
by the PAR group and the controls. Participants suffering 
from SAR were frequently sensitised to grass and birch 
while house dust mite and animal dander were the main 
antigens in PAR. In SAR as well as in PAR one participant 
(2 %) was sensitised to mold with alternaria (seasonal) or 
aspergillus (perennial) being the relevant allergen.
AR is a TH2 dominated disease. #erefore, an increase 
of TH2 cytokines and possibly a decrease of TH1 and Treg 
cytokines could be expected. Concerning the markers 
of TH2 induced B cell stimulation, we did not find ele-
vated levels of either IL-4 nor IL-13. As shown in Fig. 1a, 
similar levels of IL-4 were found in SAR (median 7  pg/
ml, range 2–17  pg/ml) and controls (median 7  pg/ml, 
range 0–32 pg/ml), but significantly lower levels in PAR 
(median 4  pg/ml, range 0–38  pg/ml) compared to con-
trols as well as to SAR (p < 0.001 vs. controls/SAR). #e 
quantity of IL-13 was decreased in SAR (median 11 pg/
ml, range 6–137  pg/ml) compared to both the controls 
(median 19  pg/ml, range 10–32  pg/ml; p  <  0.001) and 
Table 2 Demographic data and results of speci"c IgE
n.d. not determined
Controls SAR PAR
Participants (N) 48 44 45
Mean age (years) 40 37 36
Gender ♀/♂ (%) 62/38 34/66 42/58
Asthma (%) 9 24 18
Poaceae (%) n.d. 83 0
Betulaceae (%) n.d. 52 0
Asteraceae (%) n.d. 12 0
House dust mite (%) n.d. 0 82
Mold (%) n.d. 2 2
Animal dander (%) n.d. 0 27
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PAR (median 19  pg/ml, range 7–48  pg/ml; p  <  0.001) 
(Fig. 1b).
As pictured in Fig. 2a, b, a decrease of the TH1 marker 
cytokines IFN-γ and IL-12 was found in SAR (IFN-γ: 
median 85 pg/ml, range 5–299 pg/ml; p < 0.01 vs. control, 
p  <  0.001 vs. PAR; and IL-12: median 111  pg/ml, range 
45–299  pg/ml; p  <  0.001 vs. control/PAR) compared to 
PAR (IFN-γ: median 118  pg/ml, range 18–822  pg/ml; 
and IL-12: median 180 pg/ml, range 71–348 pg/ml) and 
the controls (IFN-γ: 107 pg/ml, range 34–551 pg/ml; and 
IL-12: median 200 pg/ml, range 59–358 pg/ml).
Moreover, the quantity of the mainly Treg cell released 
cytokine IL-10 was lower in SAR (median 47  pg/ml, 
range 21–139 pg/ml) than in the controls (median 73 pg/
ml, range 31–158  pg/ml; p  <  0.001) and PAR (median 
61 pg/ml, range 21–118 pg/ml; p < 0.01) (Fig. 3).
IL-17 levels, representing TH17 activity, were sig-
nificantly elevated in the SAR group (median 20  pg/
ml, range 0–90 pg/ml; p  < 0.001 vs. control/PAR) while 
the PAR group and the controls showed similar low lev-
els (PAR: median 0 pg/ml, range 0–147 pg/ml; controls: 
median 2 pg/ml, range 0–320 pg/ml) (Fig. 4).
Investigating the stimulation and activation of inflam-
matory cells, several degranulation products and 
cytokines were measured. Depicted in Fig.  5a, a com-
parison of the levels of ECP as a marker of eosinophil 
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Fig. 1 Levels of IL-4 and IL-13 in nasal fluid in controls, SAR and PAR: box plots of the levels of IL-4 (a dark grey) and IL-13 (b light grey) in nasal 
secretion are shown. IL-4 is significantly decreased in PAR compared to the controls as well as the SAR group. IL-13 is significantly decreased in SAR 
compared to both the controls and PAR. ***p < 0.001
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Fig. 2 Levels of IFN-γ and IL-12 in nasal fluid in controls, SAR and PAR: box plots of the levels of IFN-γ (a dark grey) and IL-12 (b light grey) in nasal 
secretion are shown. IFN-γ is significantly decreased in SAR compared to the controls or PAR. IL-12 is significantly decreased in SAR compared to the 
controls as well as to PAR. **p < 0.01; ***p < 0.001
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activation in nasal mucosa revealed an increase in SAR 
(median 116 ng/ml, range 0–1000 ng/ml; p < 0.001) and 
PAR (median 43  ng/ml, range 0–1000  ng/ml; p  <  0.01) 
compared to the controls (median 20  ng/ml, range 
0–467  ng/ml). Likewise, tryptase levels displaying mast 
cell activation were significantly elevated in the nasal 
secretions of the SAR (median 20 ng/ml, range 0–452 ng/
ml; p  <  0.001) and the PAR group (median 9  ng/ml, 
range 0–1000  ng/ml, p  <  0.001) compared to con-
trols (median 0  ng/ml, range 0–94  ng/ml) (Fig.  5b). As 
shown in Table 3, for G-CSF and GM-CSF, no significant 
differences among the three groups were found. Also, the 
amount of IL-1β in the nasal secretions was rather simi-
lar in all groups. Levels of IL-5 in SAR were significantly 
increased over the controls. However, no statistically 
significant difference between the controls and PAR was 
seen. #e measurement of IL-6 revealed no differences 
among the three groups.
Also displayed in Table 3 are the levels of chemokines 
in nasal discharge of AR participants and controls. An 
elevation of eotaxin was found in SAR compared to PAR. 
Concerning RANTES, higher levels were detected in 
SAR than in PAR whereas no significant difference could 
be seen between the control group and either of the AR 
groups. In comparison to the controls, elevated levels of 
MCP-1 were found in both AR groups. MIP-1α showed 
a significantly elevated level in the SAR group compared 
to control as to PAR. For MIP-1β, compared to control 
(median 103  pg/ml, range 0–2049  pg/ml), an increase 
was found in SAR (median 226 pg/ml, range 16–1769 pg/
ml; p < 0.001) as well as in PAR (median 161 pg/ml, range 
0–2138 pg/ml; p < 0.05) (Fig. 6).
Discussion
Nasal secretion is easily accessible and Bio-Plex Cytokine 
Assay is simple to perform. #us, it constitutes a method-
ological approach possibly applicable in clinical routine. 
Cytokines in the nasal fluid of participants suffering from 
SAR or PAR were analysed in a true-to-life clinical set-
ting. Aim of the present study was to investigate whether 
in AR, representative cytokines in nasal discharge show 
distinct patterns proving the used methodology helpful 
for endotyping of inflammatory nasal diseases.
For a lifelike approach, we chose to collect the samples 
neither during specific seasons of the year nor after aller-
gen provocation. In SAR, the participants’ exposition to 
aeroallergens depends not only on the absolute amount 
of antigens in the air but also on the habitation, profes-
sion and habits of the individual participant as well as 
his efforts of abstention. Likewise, it is difficult to find 
objective measurements for the individual pollination in 
PAR participants’ everyday life which also varies in the 
course of the year [18]. We thus refrained from deter-
mining the exact pollution with antigens. Moreover, not 
using subjective or objective measures of AR, we did not 
know if participants were actually suffering from AR at 
the time of sample collection. #e magnitude of the aller-
gic response is associated with the preseasonal values of 
IgE [8] and the levels of cytokines were found to differ 
between atopic and non-atopic subjects during as well as 
outside the pollen season [19]. Addressing the important 
question of trends in cytokine levels over time, longitudi-
nal studies instead of the presented cross-sectional study 
are mandatory.
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Fig. 3 Levels IL-10 in nasal fluid in controls, SAR and PAR: box plot of 
IL-10 levels in nasal secretion is shown. IL-10 is significantly decreased 
in SAR compared to the controls as well as to PAR. **p < 0.01; 
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Fig. 4 Levels IL-17 in nasal fluid in controls, SAR and PAR: box plot of 
IL-17 levels in nasal secretion is shown. IL-17 is significantly increased 
in SAR compared to both the controls and PAR. ***p < 0.001
Page 6 of 10König et al. Allergy Asthma Clin Immunol  (2015) 11:26 
IL-4 and IL-13 are produced by TH2-cells and other 
inflammatory cells such as mast cells, eosinophils 
or basophils [20]. In the pathology of allergy, similar 
responses to these cytokines are known. #ey act in 
concert or alone to induce differentiation of TH-cells, 
migration of T-cells and eosinophils, Ig class switch-
ing or mucus secretion [20, 21]. In the present study, we 
surprisingly found normal or decreased levels of these 
TH2 characterising cytokines, contradicting an expected 
upregulation, which would lead to stimulation of IgE 
production. Previous studies on IL-4 and IL-13 revealed 
normal or elevated levels in nasal secretions under nat-
ural allergen exposure, while increases were reported 
after provocation tests [9, 15, 19, 22]. One group found 
decreased levels of IL-4 in SAR patients [23]. We 
measured the cytokine levels without prior nasal allergen 
challenge, which might explain the missing elevations in 
our study. On the one hand it might be concluded that 
the amount of allergens in natural environment is not 
high enough to provoke profuse production of IL-4 and 
IL-13 but on the other hand this cannot explain decrease. 
No definite explanation can be given to the normal or 
even decreased values of IL-4 and IL-13, a methodologi-
cal cause cannot be ruled out.
Although allergy is known to be a TH2-dominated dis-
ease, the role of other T-cell subsets was also of interest 
in the presented work. IL-12 and IFN-γ are well-known 
indicators of TH1-type inflammation and crucial to 
induction and maintenance of TH1 response, activating 
preferably phagocytic and cytotoxic immune cells [24, 
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Fig. 5 Levels of ECP and tryptase in nasal fluid in controls, SAR and PAR: box plots of the levels of ECP (a dark grey) and tryptase (b light grey) in nasal 
secretion are shown. ECP is significantly elevated in SAR and PAR compared to controls. Tryptase is significantly elevated in SAR and PAR compared 
to controls. **p < 0.01; ***p < 0.001
Table 3 Cytokine levels in nasal #uid in healthy controls, SAR and PAR patients
Concentrations are given in pg/ml. Data are presented as median (upper line) and range (lower line)
n.s. not signi"cant
IL-1β IL-5 IL-6 G-CSF GM-CSF Eotaxin RANTES MCP-1 MIP-1α
Controls 20 5 25 90 32 45 9 66 0
4–1000 1–238 0–3036 9–7962 0–137 0–154 0–259 17–401 0–113
SAR 33 13 39 165 28 67 16 94 8
2–1677 0–829 5–443 10–10,681 0–115 0–503 0–766 30–600 0–66
PAR 31 6 32 146 27 30 0 93 0
5–7894 1–761 0–397 0–17,211 0–149 0–220 0–509 0–866 0–119
p values
 SAR-Con n.s. <0.05 n.s. n.s. n.s. n.s. n.s. <0.01 <0.001
 PAR-Con n.s. n.s. n.s. n.s. n.s. n.s. n.s. <0.05 n.s.
 SAR-PAR n.s. n.s. n.s. n.s. n.s. <0.001 <0.01 n.s. <0.001
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25]. Moreover, these cytokines counteract the differen-
tiation of TH2 and TH17 [24]. In our study, the levels of 
IL-12 and IFN-γ were both decreased in SAR but not in 
PAR. #is points to a downregulation of TH1-lympho-
cytes in SAR.
Having the ability to reduce Ig production and tis-
sue eosinophilia as well as TH2- and TH17-dependent 
reactions, regulatory T-cells are essential in maintain-
ing peripheral tolerance. Allergen-specific Treg-cells 
have been reported to be diminished in PAR and have 
decreased suppressive capacity in SAR [26]. IL-10 is 
an immunomodulatory cytokine which, together with 
tumor growth factor (TGF)-β, is important for Treg oper-
ability. Previous studies on the levels of IL-10 revealed 
discordant data. Unchanged or increased levels were 
found in naïve nasal secretions of SAR patients, while 
IL-10 was elevated after allergen provocation and specific 
immunotherapy [12, 22, 26]. Our results might suggest a 
diminished influence of Treg-cells in SAR, illustrating the 
impaired peripheral tolerance in AR. However, no final 
conclusion on Treg can be drawn based on our results 
as IL-10 is produced by other cell types like TH2 cells as 
well.
IL-17 is a cytokine with proinflammatory proper-
ties influencing diverse cells. IL-17 producing cells, 
named TH17, were discovered in the beginning of this 
century. Though TH17-lymphocytes were a subject 
of interest in recent years, their role in AR remains 
unclear. Scadding suspects elevated levels of this 
cytokine, predominantly in PAR [12]. Our study does 
not support this thesis, showing an elevation of IL-17 
in SAR but undetectable levels in the majority of the 
PAR samples. This is in line with a previous study 
reporting no elevation of IL-17 in nasal discharge of 
PAR patients [15].
Concerning the role of the discussed T-cell subsets 
in AR, our results suggest a downregulation of TH1 and 
Treg-lymphocytes especially in SAR. #is indicates an 
imbalance between the different T-cell subsets result-
ing in an impaired tolerance to allergens. Furthermore, 
increased markers of TH17 activity were found in AR 
leaving this T-cell subset as a field of future research.
Mast cells, activated by antigen and IgE, immediately 
release preformed mediators such as histamine, seroto-
nin, and tryptase. Moreover, stimulated mast cells newly 
produce a number of other mediators, which are released 
during the late-phase of allergic reaction [27]. We utilised 
tryptase as a marker of mast cell activation and detected 
elevated levels in both SAR and PAR. #is is concord-
ant with previous reports of elevated levels of tryptase 
caused by natural or artificial allergen exposure [28, 29] 
and emphasises the importance of mast cells in AR.
As the eosinophil is one of the predominant cell types 
in AR, we measured two indicators of eosinophil activa-
tion, ECP and IL-5. #e level of ECP, which is secreted 
by eosinophils and important in the defence of patho-
gens, correlates positively with the number of nasal 
eosinophils [14, 30]. Consistent with previous reports, 
our study found significantly elevated levels of ECP [14]. 
#e amount of nasal ECP was sixfold higher in SAR and 
doubled in PAR in comparison to the controls. IL-5, pri-
marily produced by mast cells and TH2-lymphocytes, is 
thought to be responsible for eosinophil survival, chemo-
taxis, and activation [31]. #is makes this cytokine a sec-
ond suitable indicator of eosinophil activation. Just as for 
ECP, we found elevated levels in SAR, highlighting the 
importance of eosinophils in this disease entity. However, 
the concentration of IL-5 in PAR was in normal range. 
We conclude that the role of eosinophils might be less in 
PAR than in SAR, and other factors are more important 
in maintaining the more chronic inflammation. #e ele-
vated level of IL-5 in SAR might also be a possible thera-
peutic target. Pavord et al. [32] found reduced numbers 
of eosinophils in blood samples of asthmatics treated 
with an monoclonal antibody against IL-5. In conclusion, 
we found elevated levels of markers of eosinophil activa-
tion in both AR groups. However, the effect was more 
pronounced in SAR, suggesting a greater influence of 
eosinophils in SAR than in PAR.
Concerning the next group of cytokines, the colony-
stimulating factors, surprisingly no increases could be 
shown. GM-CSF is a multifunctional proinflammatory 
cytokine produced by a host of different cells, amongst 
them epithelial cells, mononuclear cells or eosino-
phils. It acts locally in the nose stimulating dendritic 
cells as well as neutrophils and eosinophils. Moreover, 
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Fig. 6 Levels of MIP-1β in nasal fluid in controls, SAR and PAR: box 
plot of MIP-1β levels in nasal secretion. MIP-1β is significantly elevated 
in SAR as well as in PAR compared to controls. *p < 0.05; ***p < 0.001
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GM-CSF induces proliferation and differentiation of stem 
cells [33]. An increase of GM-CSF in AR patients was 
reported [9]. However, we could not reproduce this find-
ing, which might be due to the fact that our samples were 
taken without prior allergen provocation. For G-CSF, we 
did not find a statistically significant increase in either of 
the groups as well. G-CSF is known to regulate prolifera-
tion of haematopoietic progenitor cells and to influence 
neutrophil function. As most groups did not examine the 
amount of G-CSF in AR, little is known about its impact 
on AR. Pelikan [34] found elevated levels in tears of SAR 
patients after allergen provocation, providing evidence 
for an influence of G-CSF in this disease entity. But fur-
ther research is needed to define its role in allergy.
We also measured the amount of two well-established 
proinflammatory cytokines, IL-1β and IL-6. For both 
cytokines, no statistically significant difference between 
the three groups was found. IL-1β and IL-6 are rather 
unspecific markers of inflammation. Various inflamma-
tory cells are able to produce these pleiotropic cytokines. 
Physiologically, IL-1β and IL-6 influence the growth and 
maturation of immune cells as well as haematopoiesis. 
Furthermore, they are involved in auto-inflammatory dis-
eases and oncogenesis [35, 36]. Data on these two general 
markers of inflammation in nasal fluids are inconsist-
ent [12]. Pelikan [34] did not find elevated levels of IL-6 
in tears of allergic subjects. #is is consistent with our 
results, but disagrees with an elevation of IL-1β and IL-6 
found by others [9]. An explanation could be that we 
examined nasal secretions under natural allergen expo-
sure while elevated levels were described after experi-
mental allergen challenge.
#e late-response of allergic reaction is characterised 
by the influx of inflammatory cells into the site of inflam-
mation. In this process, chemokines play a crucial role. 
To measure the recruitment of eosinophils, we examined 
three chemokines potently attracting these cells: eotaxin, 
RANTES, and MIP-1α. For all three, the concentration 
in nasal secretions of SAR participants was increased. 
Eotaxin, a specific eosinophil attractant, was elevated 
in SAR over the PAR group. Our results affirm the find-
ings of Chawes et  al. [22], who found elevated levels of 
eotaxin in nasal secretions of SAR patients under natural 
allergen exposure. Moreover, an increase of eotaxin posi-
tive cells and eosinophils in nasal biopsies was reported 
after allergen provocation [37]. Concerning RANTES, 
there was a significant elevation in SAR over PAR, while 
the differences between either of the AR groups and 
the controls were not significant. RANTES is not only 
known to attract eosinophils but also to cause activa-
tion of eosinophils and basophils resulting in inflamma-
tory mediator release [21]. Further, elevated levels were 
reported after nasal allergen challenge [9]. #e levels of 
MIP-1α were significantly increased in SAR participants. 
MIP-1α is produced by a number of inflammatory cells 
and is able to attract granulocytes as well as to activate 
eosinophils, to stimulate T-cells and to regulate Ig pro-
duction [21, 38]. It is reported to be elevated after nasal 
allergen challenge [9, 12]. Interestingly, this chemokine 
was not detectable in the majority of our controls or PAR 
participants, while in SAR, most participants had detect-
able levels of MIP-1α. In summary, our results show an 
increase of eosinophil attractants in SAR. #is is in line 
with the elevated levels of ECP and IL-5, emphasising the 
prominent role of eosinophils in SAR, while the normal 
levels of IL-5 and just slightly elevated levels of ECP in 
PAR indicate a minor role of eosinophils in the chronic 
inflammation of PAR.
#e levels of MCP-1 and MIP-1β were elevated in 
either of the AR groups. Increased MCP-1 and MIP-1β 
release has been reported under natural exposure as well 
as after allergen provocation in SAR subjects [12, 22]. 
MCP-1 potently attracts and activates monocytes and 
basophils, and recruits macrophages and neutrophils 
[38, 39]. Secreted by monocytes, natural killer cells and 
activated lymphocytes, MIP-1β recruits lymphocytes, 
natural killer cells and immature dendritic cells [40]. #e 
elevation of these two chemokines clearly shows that in 
both SAR and PAR, a bunch of diverse inflammatory cells 
is recruited. Our results thus support the concept of min-
imal persistent inflammation in PAR [41]. #is concept 
states a persistent infiltration of neutrophils under con-
tinuous low allergen exposure while eosinophils and mast 
cells have minor influence.
Conclusions
Aim of our study was to find distinct cytokine profiles in 
nasal discharge of AR participants in a lifelike approach, 
which might be useful for diagnostic purposes. Evaluat-
ing our results, ECP, tryptase, MCP-1, and MIP-1β are 
suitable markers to differentiate AR participants from 
healthy subjects. Furthermore, in SAR eotaxin, MIP-1α, 
and IL-17 are elevated in comparison to both PAR par-
ticipants as well as controls. In addition, reduced levels of 
IFN-γ and IL-10 are found. Moreover, SAR and PAR can 
be distinguished by the levels of RANTES. Even though 
some questions remain unanswered, we have demon-
strated that the methodology used in this study could 
be developed into a diagnostic tool for “endotyping” of 
patients in daily clinical routine. If such an “endotyping” 
is feasible in nasal discharge, this method is superior to 
immunohistochemical analysis of nasal biopsy specimen 
because nasal discharge is easily accessible and collec-
tion is harmless to the patient. Further research is needed 
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to describe the cytokine patterns in nasal fluid of pure 
CRS with or without nasal polyps followed by examina-
tions of mixed forms of CRS and AR. In the long term, 
easily accessible biomarkers could help to match patients 
with innovative therapeutic approaches like anti-cytokine 
antibodies. Uncovering specific endotypes out of clini-
cally similar phenotypes might result in a more targeted, 
individualised therapy beneficial to the patient.
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Cytokine patterns in nasal secretion 
of non-atopic patients distinguish 
between chronic rhinosinusitis with or 
without nasal polys
Katrin König1, Christine Klemens1, Mareike Haack1, Marion San Nicoló1, Sven Becker1,2, Matthias F. Kramer1 
and Moritz Gröger1*
Abstract 
Background: Being one of the most common nasal diseases, chronic rhinosinusitis (CRS) is subdivided into CRS with 
nasal polyps (NP) and CRS without nasal polyps (CRSsNP). CRSsNP presents itself with a TH1 milieu and neutrophil infil-
tration, while NP is characterised by a mixed TH1/TH2 profile and an influx of predominantly eosinophils, plasma cells 
and mast cells. For the purpose of discovering disease-specific cytokine profiles, the present study compares levels of 
mediators and cytokines in nasal secretions between CRSsNP, NP, and healthy controls.
Methods: The study included 45 participants suffering from NP, 48 suffering from CRSsNP and 48 healthy controls. 
Allergic rhinitis constituted an exclusion criterion. Nasal secretions, sampled using the cotton wool method, were 
analysed for IL-4, IL-5, IL-10, IL-12, IL-13, IL-17, IL-8, GM-CSF, G-CSF, IFN-γ, MCP-1, MIP-1α, MIP-1β, eotaxin, and RANTES, 
and for ECP and tryptase, using Bio-Plex Cytokine assay or ELISA, respectively.
Results: Elevated levels of IL-5, IL-17, G-CSF, MCP-1, MIP-1α, MIP-1β, ECP, and tryptase, as well as decreased levels of 
IL-10, IL-12, IL-13, and IFN-γ were detected in NP. CRSsNP presented increased levels of RANTES and MIP-1β while IL-13 
was decreased. No differences between the three groups were found for IL-4, IL-8, GM-CSF, and eotaxin.
Conclusions: The present work suggests a disequilibrium of TH1 and TH2, together with a down-regulation of regula-
tory T lymphocytes and up-regulated TH17 in NP. Moreover, elevated levels of diverse mediators represent the activa-
tion of various inflammatory cells in this disease entity. The inflammation in CRSsNP, however, is only weakly depicted 
in nasal secretions. Therefore, cytokines in nasal secretions may provide helpful information for differential diagnosis.
Keywords: Chronic rhinosinusitis, Nasal polyps, Nasal discharge, Mediators, Cytokines, Chemokines
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Background
Chronic rhinosinusitis (CRS) is one of the most common 
nasal diseases, affecting 5 % of the Canadian population 
and 11 % of Europeans [1, 2]. Deteriorating both physi-
cal and mental health, CRS significantly impairs patients’ 
quality of life and imposes immense costs on the public 
health system [3, 4]. CRS is characterised by an inflam-
mation of the nose and paranasal sinuses for more than 
12 weeks, causing nasal obstruction and discharge, facial 
pain, and reduction of smell [5]. By nasal endoscopy, this 
disease is subdivided into CRS with nasal polyps (NP) 
and CRS without nasal polyps (CRSsNP) [5].
Nasal polyps manifest themselves macroscopically as 
grey masses, prolapsing into the nasal cavity. In histologi-
cal sections, oedema, pseudocysts, and a colourful infil-
trate of inflammatory cells are seen. In contrast, CRSsNP 
is characterised by fibrosis and basement membrane 
thickening [6].
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#e pathophysiology of CRS is not yet well understood. 
Although CRS may be associated to genetic or systemic 
diseases such as cystic fibrosis or sarcoidosis, the major-
ity of the CRS patients seems to suffer from idiopathic 
disease [7]. Concerning the aetiopathology, local and sys-
temic host factors as well as environmental factors have 
been discussed [8]. However, hypotheses about impaired 
innate immunity, fungi, or superantigens remain to 
be verified. Atopic diseases are more frequent in CRS 
patients than in the general population, and allergy as an 
associated or deteriorating factor has also been discussed 
[9]. Yet, a definitive answer is owing.
According to reported cell and cytokine patterns, 
CRSsNP and NP seem to be different disease entities. 
CRSsNP is characterised by a TH1 milieu and neutro-
phils. NP, on the other hand, shows a mixed TH1/TH2 
profile with increased numbers of eosinophils, plasma 
cells and mast cells [6, 10]. However, this only applies 
to the majority of the Caucasian NP patients; Asian NP 
patients have been reported to show a TH1/TH17 polari-
sation, while the T cell patterns of CRSsNP were similar 
in both races [6, 11, 12].
#e present work compares cytokines in nasal secre-
tions of NP and CRSsNP patients to those of healthy 
subjects. In the present study, we wanted to study CRS 
in pure form. As interference between the pathophysi-
ological processes of allergic rhinitis and CRS is conceiv-
able, allergy testing was performed to exclude allergic 
patients from the study. Levels of cytokines were inves-
tigated in order to determine whether the pathophysi-
ology of CRS is depicted in nasal secretions. Our study 
focusses on two major aspects: the regulation of the T 
cell subsets TH1, TH2, TH17, and regulatory T cells (Treg), 
represented by levels of interleukin (IL)-4, IL-5, IL-10, 
IL-12, IL-13, IL-17, and Interferon (IFN)–γ, and the 
regulation and activation of inflammatory cells such as 
granulocytes and mast cells by levels of IL-5, IL-8, gran-
ulocyte–macrophage colony-stimulating factor (GM-
CSF), granulocyte colony-stimulating factor (G-CSF), 
eotaxin, “regulated on activation, normal T cell expressed 
and secreted” (RANTES) protein, macrophage inflamma-
tory protein (MIP)-1α, MIP-1β, monocyte chemotactic 
protein-1 (MCP-1), eosinophil cationic protein (ECP), 
and tryptase.
Methods
Study population
141 volunteers (64 males, 77 females, mean age 
41 ± 15 years) participated in the present study. Clinical 
history was taken by one of the investigators. All subjects 
were tested for allergy to aeroallergens with the in vitro 
allergy screening test Sx1 (Phadia, Freiburg, Germany). 
Based on a fluorescence-enzyme-immunoassay (FEIA) 
this method tests for IgE to inhalant allergens in partici-
pants’ sera. Volunteers presenting a history of allergy or a 
positive Sx1 were excluded from the study.
Any medication concerning the nasal disease during 
6  weeks prior to the examination constituted an exclu-
sion criterion, particularly anti-inflammatory medica-
tion such as topical nasal steroids. To detect nasal polyps 
and exclude patients with signs of purulent rhinitis, nasal 
endoscopy was performed in all volunteers. For ethical 
reasons, X-ray computed tomography (CT) scanning was 
only performed if indicated for medical care, but not for 
the purpose of this study.
NP (n  =  45) was determined by the patient’s history 
and the presence of endoscopically visible polyps in the 
nasal cavity, the paranasal sinuses, or both.
CRSsNP (n = 48) was determined clinically by typical 
complaints in the patient’s history such as midfacial pain 
or pressure, postnasal drip, nasal obstruction, or reduc-
tion of smell. Inspection of the nose and nasal endoscopy 
revealed the picture of a chronic mucosal inflammation 
in the absence of polyps.
Healthy controls (n  =  48) presented no history of 
inflammatory nasal complaints and normal findings in 
the endoscopic examination.
#e study was approved by the ethics committee of 
the medical faculty of Ludwig-Maximilians-University 
in Munich, Germany, and written informed consent was 
obtained from all participants.
Biochemical and immunological methods
Nasal secretions were gained and processed with minor 
modifications as described by Rasp and co-workers [13]: 
For the sampling of nasal secretions, small cone-shaped 
cotton wool pieces (absorbent cotton, Hartmann, Hei-
denheim/Brenz, Germany) with a length of about 3 cm 
and a diameter of about 6  mm were used. After posi-
tioning the cotton wool pieces in the middle meatus of 
the nose, they were left in place for 20 min and subse-
quently centrifuged (+4 °C, 2000g) on a sieve for 10 min 
[14].
Diluted 1:5, all samples were analysed for IL-4, IL-5, 
IL-10, IL-12, IL-13, IL-17, IL-8, GM-CSF, G-CSF, IFN-γ, 
MCP-1, MIP-1α, MIP-1β, eotaxin, and RANTES using 
a human cytokine 17-plex panel (Bio-Plex Cytokine 
Assay, Bio-Rad Laboratories, Hercules, California). #is 
cytokine assay uses fluorescently-addressed polystyrene 
beads with conjugated capture antibodies directed to 
the aforesaid cytokines. After washing, a fluorescently 
marked detection antibody builds an immunoassay with 
the cytokine. For analysis, two lasers excite the fluoro-
chromes: one for classifying each bead, the other for 
quantifying the amount of analyte bound [15]. #e detec-
tion threshold was 0.5 pg/ml.
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ECP and tryptase were measured by ELISA (UniCAP-
FEIA, Phadia, Freiburg, Germany). Detection levels were 
10 ng/ml for ECP, and 5 ng/ml for tryptase.
Statistics
SigmaPlot for Windows version 11.0 software (Systat 
Software, San José, California, USA) was utilised for sta-
tistical evaluation and graphical presentation. As all data 
failed normality testing (Shapiro–Wilk), the Kruskal–
Wallis one way analysis of variance (ANOVA) on Ranks 
was used, testing for statistically significant difference in 
the median values among the three groups. To isolate the 
group or groups that differ from the others, the all pair-
wise multiple comparison procedures (Dunn’s Method) 
was used in the following step. To reduce the false discov-
ery rate, the method of Benjamini and Yekutieli was used 
[16]. Data are given as median and range. For graphic 
presentation, data are displayed in a box plot with the 
median (horizontal line within the box), the 25th and 
75th percentile (boundary of the box), and the 10th and 
90th percentile (whiskers above and below the box). Sig-
nificances are graphically represented between the corre-
sponding plots: * indicates p value <0.05, ** p value <0.01, 
and *** p value <0.001.
Results
In total, 141 participants were included in this study, 45 
people suffering from NP (28 males, 17 females; mean 
age 42 ± 15 years), 48 suffering from CRSsNP (18 males, 
30 females; mean age 42 ± 15 years) and 48 healthy sub-
jects (18 males, 30 females; mean age 40 ± 16 years).
#e levels of TH2 related cytokines presented an inho-
mogeneous picture (Table 1). For IL-4, the three groups 
showed no significant differences. #e level of IL-5 
was increased in NP in comparison to CRSsNP, while a 
comparison between either of both groups of chronic 
rhinosinusitis versus controls revealed no differences. 
As shown in Fig.  1, CRSsNP (median 15  pg/ml, range 
2–92 pg/ml; p < 0.01 vs. controls and vs. NP) as well as 
NP (median 10  pg/ml, range 4–62  pg/ml; p  <  0.001 vs. 
controls) presented reduced amounts of IL-13 (controls: 
median 19 pg/ml, range 10–32 pg/ml).
Compared to the controls and CRSsNP, the quanti-
ties of TH1 associated cytokines IL-12 (Fig.  2a), as well 
as IFN-γ (Fig. 2b) were decreased in NP (IL-12: median 
108  pg/ml, range 17–211  pg/ml, p  <  0.001 vs. con-
trols and vs. CRSsNP; INF-γ median 63  pg/ml, range 
0–308  pg/ml, p  <  0.001 vs. controls and p  <  0.01 vs. 
CRSsNP). CRSsNP (IL-12: median 158  pg/ml, range 
60–318 pg/ml; INF-γ median 102 pg/ml, range 0–683 pg/
ml) did not differ from the controls (IL-12: median 
200  pg/ml, range 59–358  pg/ml; INF-γ median 107  pg/
ml, range 34–551 pg/ml).
Likewise, IL-10 (Fig.  3), a Treg related cytokine, was 
decreased in NP (median 41  pg/ml, range 8–72  pg/
ml) compared to controls (median 73  pg/ml, range 
31–158 pg/ml; p < 0.001) as well as to CRSsNP (median 
74 pg/ml, range 20–118 pg/ml; p < 0.001).
In contrast to these diminished cytokine levels, the 
TH17 respective cytokine IL-17 (Fig.  4) was elevated 
in nasal secretions of NP patients (median 15  pg/ml, 
range 0–105  pg/ml) in comparison to controls (median 
2 pg/ml, range 0–320 pg/ml; p < 0.001) and to CRSsNP 
(median 2 pg/ml, range 0–146 pg/ml; p < 0.001).
Mast cell activation was seen in NP patients by ele-
vated levels of tryptase in nasal secretion, as indicated 
in Fig.  5a (NP median 11  pg/ml, range 0–75  pg/ml; 
controls: median 0  pg/ml, range 0–94  pg/ml; CRSsNP 
median 0  pg/ml, range 0–75  pg/ml; p  <  0.001 vs. con-
trols). Additionally, ECP (Fig.  5b), a marker of eosino-
phil activation, was increased in NP (NP median 56 pg/
ml, range 0–1000  pg/ml; controls: median 20  pg/ml, 
Table 1 Cytokine levels in nasal "uid in healthy controls, NP and CRSsNP participants
Concentrations are given in pg/ml. Data are presented as median (upper line) and range (lower line). To control the false discovery rate, we used the method of 
Benjamini and Yukatieli. Thus, values marked with ‘*’ are regarded as non-signi#cant despite p < 0.05
n.s. not signi#cant; s. signi#cant
IL-4 IL-5 IL-8 IL-13 Eotaxin GM-CSF RANTES MCP-1 MIP-1α
Controls 7
0–32
5
1–238
1310
189–42,868
19
10–32
45
0–154
32
0–137
9
0–259
66
17–401
0
0–113
NP 7
0–17
10
0–500
1851
0–265,037
10
4–62
75
0–422
27
0–112
14
0–563
117
13–3867
6
0–60
CRSsNP 5
0–30
3
1–1831
1877
0–1,384,113
15
2–92
49
0–339
42
0–132
35
0–426
89
0–1676
0
0–673
P values
 NP—Con n.s. (0.822) n.s. (0.070) n.s. (0.562) s. (< 0.001) n.s. (0.114) n.s. (0.286) n.s. (0.447) s. (< 0.001) s. (< 0.001)
 CRSsNP—Con n.s. (0.133) n.s. (0.025)* n.s. (0.291) s. (< 0.01) n.s. (0.361) n.s. (0.456) s. (< 0.050) n.s. (0.028)* n.s. (0.028)*
 NP—CRSsNP n.s. (0.213) s. (<0.001) n.s. (0.887) s. (< 0.01) n.s. (0.315) n.s. (0.148) n.s. (0.079) n.s. (0.024)* n.s. (0.037)*
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range 0–467  pg/ml; CRSsNP median 45  pg/ml, range 
0–1000 pg/ml; p < 0.001) while the quantity of eotaxin in 
nasal discharge showed no statistically significant differ-
ences among groups (Table 1).
Neutrophil associated factors such as IL-8 (Table  1) 
partially showed a non-significant elevation in nasal 
secretion from patients with chronic rhinosinusitis 
either with or without nasal polyps. While in NP G-CSF 
(Fig.  6) was increased threefold over the controls (NP 
median 277 pg/ml, range 0–9802 pg/ml; controls: median 
90 pg/ml, range 9–7962 pg/ml; CRSsNP: median 155 pg/
ml, range 0–8611  pg/ml; p  <  0.01), levels of GM-CSF 
(Table 1) were not different among groups.
Quantities of chemoattractant proteins were increased 
in chronic rhinosinusitis. MCP-1 and MIP-1α were sig-
nificantly elevated in NP only (Table 1). Irrespective of the 
existence of nasal polyps, levels of MIP-1β (Fig.  7) were 
significantly increased in NP (median 251  pg/ml, range 
12–2088 pg/ml; p < 0.001) as well as in CRSsNP (median 
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Fig. 1 Levels of IL-13 in nasal fluid in controls, NP and CRSsNP: box 
plots of the levels of IL-13 in nasal secretion is shown. IL-13 is signifi-
cantly decreased in NP compared to both CRSsNP and the controls. 
Moreover, IL-13 is decreased in CRSsNP compared to the controls. 
**p < 0.01, ***p < 0.001
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Fig. 2 Levels of IL-12 and IFN-γ in nasal fluid in controls, NP and CRSsNP: box plots of the levels of IL-12 (a dark grey) and IFN-γ (b light grey) in nasal 
secretion are shown. IL-12 as well as IFN-γ are significantly decreased in NP compared to both CRSsNP and the controls. **p < 0.01, ***p < 0.001
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Fig. 3 Levels of IL-10 in nasal fluid in controls, NP and CRSsNP: box 
plot of IL-10 levels in nasal secretion is shown. IL-10 is significantly 
decreased in NP compared to the controls as well as to CRSsNP. 
***p < 0.001
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182  pg/ml, range 0–5296  pg/ml; p  <  0.01) over controls 
(median 103  pg/ml, range 0–2049  pg/ml). Concerning 
RANTES, a statistically significant increase was found 
only in CRSsNP compared to the controls, whereas levels 
in NP did not differ from the other groups (Table 1).
Discussion
#is study is part of an extensive project, aiming for dis-
tinct cytokine patterns in chronic nasal diseases. CRS 
seems to be a heterogeneous group of diseases presenting 
not only different phenotypes like CRS with or without 
nasal polyps but also consisting of diverse endotypes. 
New therapeutic approaches with biologic agents are cur-
rently in development [17]. #ese new approaches neces-
sitate patient selection by biomarkers. To determine this 
reason, there is demand for tools helping to define endo-
types as well as to select suitable patients for therapies 
with anti-cytokine antibodies. Bio-Plex Cytokine Assay in 
nasal secretion could be such a tool as collection of nasal 
discharge is an easy procedure harmless to the patient, 
and the assay is simple to perform. #us, it constitutes a 
methodological approach possibly applicable in clinical 
routine. We therefore have already analysed cytokines 
in nasal secretions of patients with allergic rhinitis in a 
true-to-life clinical setting as a first step [18]. In the pre-
sent study, we measured the amount of cytokines in nasal 
fluid of participants suffering from NP or CRSsNP as well 
as healthy controls. #e aim of the current study was to 
investigate whether in CRS with or without nasal polyps, 
representative cytokines in nasal discharge show distinct 
patterns proving the used methodology helpful for endo-
typing inflammatory nasal diseases. In the long term, we 
aim for providing easily accessible biomarkers allocating 
patients to specific endotypes and therapies.
IL-4, IL-5, and IL-13 are usually regarded as TH2 
cytokines, being predominantly involved in the humoral 
immune response. #ese cytokines are not only pro-
duced by TH2 lymphocytes but also by other cells 
involved in this response pattern, such as plasma cells, 
mast cells, and eosinophils [10, 19]. For IL-4, we did not 
find any differences between the three groups, which is in 
accordance with previous findings [20]. However, other 
authors observed an elevation in nasal secretions in NP, 
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Fig. 4 Levels of IL-17 in nasal fluid in controls, NP and CRSsNP: 
box plot of IL-17 levels in nasal secretion is shown. IL-17 is signifi-
cantly increased in NP compared to both the controls and CRSsNP. 
***p < 0.001
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Fig. 5 Levels of tryptase and ECP in nasal fluid in controls, NP and CRSsNP: box plots of the levels of tryptase (a dark grey) and ECP (b light grey) in 
nasal secretion are shown. Tryptase and ECP are significantly elevated in NP compared to controls. ***p < 0.001
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and a correlation between IL-4 levels and the patients’ 
CT scores was described [21, 22]. IL-4, as well as IL-13, 
supports the expression of a TH2 inflammatory pat-
tern by modulating lymphocyte differentiation, inducing 
IgE production, and facilitating eosinophil infiltration 
by the up-regulation of chemoattractants and adhesion 
molecules [19, 23]. Moreover, in  vitro studies revealed 
a negative influence of IL-4 on the epithelial integrity in 
NP [24]. We surprisingly found decreased levels of IL-13 
in both CRS groups, contradicting previous reports of an 
up-regulation of IL-13 mRNA in NP [22, 25]. Using the 
same control group, we unexpectedly detected decreased 
levels in allergic rhinitis patients in a previous study [18]. 
#is might imply a methodical error forming the basis of 
the decreased amounts of IL-13. We are not able to offer 
a suitable concept for this unexpected result. Concern-
ing IL-5, detected levels in CRSsNP and NP were not sig-
nificantly different from controls. However, the amount 
of IL-5 in NP secretions was significantly higher than in 
CRSsNP. Several authors found elevated levels of this 
cytokine [25–27]. IL-5 is a hematopoietic growth factor 
and crucial for the survival and maturation of eosinophils 
at the site of inflammation [19, 23]. #erefore, it is dis-
cussed as a possible therapeutic target in NP and studies 
with anti-IL-5 monoclonal antibodies show auspicious 
results [28].  In conclusion, our results indicate a down-
regulation of TH2 lymphocytes in CRSsNP. Furthermore, 
they rebut an expected up-regulation in NP and are 
opposed to the general assumption that the majority of 
Caucasian NP patients show a TH2 pattern of inflamma-
tion with elevations of TH2-type cytokines.
IL-12 and IFN-γ are indicators of TH1 lymphocyte 
activity. Both cytokines were decreased in NP compared 
to both the controls and CRSsNP, indicating a down-
regulation of TH1 cells in nasal polyposis. Others found 
up-regulated or unchanged levels of IFN-γ and IL-12 in 
NP and CRSsNP [27, 29]. However, these studies used 
tissue samples instead of nasal secretions. Both IL-12 and 
IFN-γ induce a predominantly cellular immune response, 
involving cytotoxic cells and macrophages. #ey pro-
mote TH1 differentiation and counteract TH2 and TH17 
development [30]. Moreover, they influence neutrophil 
survival as well as epithelial integrity [24, 31]. In a study 
on mice, IFN-γ expression was shown to be associated 
with deteriorated olfactory function [32]. Accordingly, 
this cytokine might be considered a therapeutic target for 
treating the burdensome reduction of smell in patients 
suffering from CRS.
IL-10 was used as a reference to the role of Treg in 
CRS. A decrease was detected in NP which fits the find-
ings of Kim et  al. who detected impaired migration of 
regulatory T cells in NPs [33]. #is points to a derogated 
immunomodulation in the mucosa of NPs. Furthermore, 
the level of IL-17 was sevenfold higher in NP than in the 
controls or CRSsNP. IL-17 is characteristic for TH17 lym-
phocytes and a proinflammatory cytokine affecting neu-
trophils and eosinophils [34, 35]. Data on IL-17 is still 
ambiguous. While elevated levels have been described 
in Chinese NP patients, studies on Caucasians reveal 
conflicting results, ranging from elevated to reduced 
amounts [12, 25, 36]. #us, further research on this 
topic might be needed. In conjunction with the afore-
said results, we state that a relative ascendancy of TH2 
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Fig. 6 Levels of G-CSF in nasal fluid in controls, NP and CRSsNP: box 
plot of G-CSF levels in nasal secretion. G-CSF is significantly elevated 
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Fig. 7 Levels of MIP-1β in nasal fluid in controls, NP and CRSsNP: box 
plot of MIP-1β levels in nasal secretion. MIP-1β is significantly elevated 
in NP and CRSsNP compared to controls. **p < 0.01, ***p < 0.001
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over TH1 as well as an up-regulation of TH17 was seen 
in NP while an impaired function of Treg suggests itself 
in this disease entity. CRSsNP, however, showed normal 
quantities of all cytokines except for decreased levels 
of the TH2 cytokine IL-13. Our results argue for a more 
severe inflammation in NP, whereas the inflammation in 
CRSsNP was only weakly depicted in nasal secretions.
Eosinophilic inflammation has frequently been described 
in the nasal mucosa of patients suffering from NP. As men-
tioned, IL-5, a cytokine inducing survival and activation 
of eosinophils was elevated in NP compared to CRSsNP. 
Another major factor in eosinophilic inflammation is 
eotaxin. It is up-regulated preferably by TH2 and potently 
attracts eosinophils [10, 37, 38]. Elevated levels were found 
in the sinunasal mucosa of CRS patients as well as in nasal 
secretions of NP patients [27, 39]. In our study highest lev-
els were also seen in NP, however differences between the 
three groups did not reach statistical significance. #e lev-
els of ECP, on the other hand, were significantly elevated in 
NP but not in CRSsNP. ECP is a protein holding antimicro-
bial as well as modulatory properties [40]. Plenty of reports 
of elevations of ECP levels in different nasal diseases exist, 
indicating that ECP is rather a general marker of inflamma-
tion than disease-specific [14, 29, 41]. Our results suggest 
an infiltration of eosinophils into the mucosa of nasal pol-
yps but not into the mucosa of CRSsNP. In allergic rhinitis, 
mast cells have frequently been investigated, and much is 
known about their role in the early-phase of allergic reac-
tion [42]. We detected elevated levels of tryptase in nasal 
secretions of the NP patients. #is is in conformity with 
findings from others describing an increased amount of 
mast cells and tryptase in mucosal tissue and nasal secre-
tions of NP patients. Further, the level of tryptase in nasal 
secretions correlated with nasal obstruction and rhinor-
rhoea [14, 43]. #is might suggest a benefit from mast cell 
targeting medication in NP.
Di Lorenzo and colleagues reported that the levels of 
tryptase and ECP in NP exceeded those in allergic rhini-
tis [44]. We compared the levels of these two mediators 
in NP with the previously reported levels in allergic rhi-
nitis (AR) [18]. For ECP and tryptase, the levels in sea-
sonal AR were twice as high as in NP, while the values in 
perineal AR were slightly lower than in NP. However, in 
contrast to the findings of Di Lorenzo and co-workers, 
in our study, the differences between the levels in NP 
and AR did not reach statistically significance. Di Lor-
enzo et al. gained their samples by nasal lavage while we 
used the cotton wool method. ECP release was found 
to be higher in polyps than in the lower turbinate of NP 
patients [45]. Probably, the amount of ECP and tryptase 
would be higher under assured placement of the cotton 
wool pieces on the polyp. #is might explain the differ-
ence to Di Lorenzo’s results.
Neutrophil infiltration has been seen in both CRSsNP 
and NP [46]. In order to get indication of neutrophil 
attraction, we measured the levels of IL-8 and detected 
elevated amounts in both CRS groups but not reaching 
a level of significance. Others report a more pronounced 
increase of IL-8 in NP [47, 48].
#e colony-stimulating factors delay neutrophil death 
[31]. While G-CSF influences proliferation and differen-
tiation of neutrophil progenitor cells as well as the func-
tion of mature neutrophils, GM-CSF often appears in 
the context of recruitment, activation, and survival of 
eosinophils [38, 49]. Concerning G-CSF, we found levels 
threefold higher in NP than in controls. GM-CSF was in 
a normal range in the nasal secretions in CRS, irrespec-
tive of nasal polyps, as opposed to elevations described 
in tissue samples of NP patients [50]. In summary, we saw 
no definite evidence of increased neutrophil attraction by 
IL-8, but elevated levels of G-CSF in NP might indicate a 
role of this type of granulocyte in polyposis.
In addition, different chemokines were examined. 
RANTES was elevated in CRSsNP but not in NP, others 
reported increased levels of RANTES in tissue samples of 
polyps [50, 51]. RANTES is known to attract eosinophils, 
basophils and mast cells, and is present in nasal secre-
tions during ongoing infection [38, 52, 53]. Plasma lev-
els of RANTES have been found to correlate with disease 
severity [54]. In contrast to RANTES, we found MCP-1 
to be elevated in NP. MCP-1 attracts different inflamma-
tory cells, among them monocytes and T cells. In CRS, 
increased amounts of MCP-1 have been reported in nasal 
secretions as well as in nasal mucosa biopsies [29, 55].
Two other chemokines, MIP-1α and MIP-1β, are struc-
turally related proteins, with 68  % of their amino acids 
being identical [56]. Produced by a host of inflammatory 
cells, they both have a number of cellular targets, such 
as monocytes and dendritic cells. However, only MIP-1α 
is ascribed to attract granulocytes [56, 57]. In our study, 
increased amounts of MIP-1α were detected in poly-
posis patients while being undetectable in the majority 
of the CRSsNP patients and controls. MIP-1β, on the 
other hand, showed elevated levels in both CRSsNP and 
NP. Peric and co-workers found a correlation between 
MIP-1α levels in nasal secretions and endoscopic and 
CT scores in NP [57]. Moreover, MIP-1α gene expression 
was elevated in patients with early recurrence of polyps 
after surgery over those being treatment-responsive [50]. 
Further research is needed to evaluate the diagnostic and 
prognostic utility of this chemokine in CRS.
In conclusion, the evaluation of the chemokines and 
growth factors in the present study revealed an eleva-
tion of G-CSF, MCP-1, MIP-1α, and MIP-1β in NP, 
while CRSsNP shows increased levels of RANTES and 
MIP-1β only. We conclude that a number of different 
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inflammatory cells are involved in NP and inflammation 
is more pronounced in NP than in CRSsNP.
Conclusions
Colleagues from Belgium recently emphasised in their 
review “Emerging biologics for the treatment of chronic 
sinusitis”: “#e greatest challenge for the future is to 
define the different endotypes of CRSwNP using eas-
ily accessible biomarkers to select the patients who have 
the best chance of a positive therapeutic response to 
innovative approaches.” [58]. With the present study, we 
tried to take a closer look exactly on this topic evaluating 
cytokine profiles in participants suffering from CRS with 
or without nasal polyps.
Overall, we found a more pronounced inflammatory 
profile in NP than in CRSsNP. IL-5, IL-10, IL-12, IL-17, 
and IFN-γ represent a disequilibrium of T cells in NP, 
and ECP, tryptase, G-CSF, MCP-1, MIP-1α, and MIP-1β 
depict the activation of various inflammatory cells in this 
disease entity. CRSsNP participants, on the other hand, 
did not differ much from healthy individuals. Merely 
RANTES and MIP-1β seem to be suitable mediators to 
distinguish between CRSsNP and healthy individuals. 
As we did not detect any significant differences between 
the three groups for IL-4, IL-8, GM-CSF, and eotaxin, we 
conclude that these mediators are not of distinctive func-
tion in chronic rhinosinusitis.
In the long term, we aim to evaluate multiplex-analyses 
of cytokines in nasal discharge being a suitable diagnostic 
tool for the “endotyping” of patients with chronic sinona-
sal diseases. To us, this is a crucial step for selection of 
patients with regard to a therapy with biologic agents, 
especially anti-cytokine antibodies. #e sampling of nasal 
secretions is an easily performable and non-invasive 
method and could benefit many patients if established 
as a diagnostic and prognostic tool. However, further 
research regarding suitable indicators of different nasal 
diseases and the establishment of norm values is needed 
to attain this goal. #us, therapies tailored to the indi-
vidual patient’s needs should become accessible in the 
future.
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